BERLIN & NEVADA--(BUSINESS WIRE)--GBC Research, an independent German research house focusing on listed small and midcap companies, has initiated the coverage on MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, with a "Buy" recommendation and a price target of EUR 13.20. MagForce's shares closed on Tuesday, May 19, 2015 at EUR 5.63 on Xetra. Hence, the GBC analysis values the Company with